Dr. Aditi Singh

215 posts

Dr. Aditi Singh banner
Dr. Aditi Singh

Dr. Aditi Singh

@pulmoncdoc

Thoracic, Head and Neck Oncologist @VAMinneapolis, assistant professor of medicine @UMNews, thoracic Fellow @Mayocancercare, MPH @JohnsHopkinsSPH

Minneapolis, MN Katılım Şubat 2016
1.3K Takip Edilen401 Takipçiler
Dr. Aditi Singh retweetledi
JTO & JTO CRR
JTO & JTO CRR@JTOonline·
Carbone et al. showed that mesothelioma in patients with the BAP1+/- mutation is biologically, histologically, and clinically distinct, requiring a tailored treatment approach. Read more in this month's JTO: bit.ly/3K5KSBj
JTO & JTO CRR tweet media
English
0
16
22
3.1K
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
Press release!!! And just as a reminder- benefit of io/vegf bispecifics believed to come from “cooperative” binding via VEGF dimers leading to more avid inhibition of pd1/pd-l1 as well as vegf/vegfr axis And with all the excitement- there is now a bit of a queue to get to the top of the IO Mt Everest Summit!
Balazs Halmos tweet mediaBalazs Halmos tweet mediaBalazs Halmos tweet mediaBalazs Halmos tweet media
Balazs Halmos@BalazsHalmosMD

Chemo/Ivonescimab “decisively” beat chemo/tisleluzimab in adv Sq NSCLC- interesting choice of words.. Are PD-(L)1/VEGF bispecifics reaching the Summit now with 3rd randomized study reading out positively? After a decade of King Keytruda rule, are we ready to “decisively” crown a new Queen in the IO space?

English
3
4
27
3.5K
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
Merck shakes the HN oncology Earth! KN689 results leading to FDA filing- as compared to disappointing adjuvant IO results ala Javelin etc, perioperative pembro for resectable LA HNSCC yielding improved EFS and increased mPR rates- further expanding the horizons of neoadjuvant therapy!
GIF
Merck@Merck

We're pleased to announce the #FDA has accepted our filing related to a potential treatment option for certain patients with head and neck cancer. Learn more here: merck.us/4hdkMqJ

English
2
2
19
1.9K
Dr. Aditi Singh retweetledi
Thor Halfdanarson
Thor Halfdanarson@OncoThor·
Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo. @ALLIANCE_org nejm.org/doi/full/10.10…
English
7
21
53
5.7K
Dr. Aditi Singh retweetledi
Marie Suga, MD
Marie Suga, MD@jmsuga·
Do we need to do cardiac monitoring for all patients on Osimertinib? Congrats to Dr Francisco Martinez, recent KPSF fellowship graduate’s poster at #wclc2024 Bottom line: >800 pts, 3700 ECHOs, only 10 Osi HF events Higher in a fib, CHF hx pts @KPDOR @Rayliukpsfo @LoriSakoda
Marie Suga, MD tweet media
English
1
2
16
728
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
Mentorship 101: Important to check on your mentees even after they start a new job- like Eçe at Wash U- even if one has to drive 1000+ miles for it!😉 I took the effort to introduce her to new skills, like eating alligator tacos.. Great to see you taking a fantastic start, Eçe!
Balazs Halmos tweet mediaBalazs Halmos tweet media
Balazs Halmos tweet media
English
5
0
35
6K
Dr. Aditi Singh retweetledi
Only In Boston
Only In Boston@OnlyInBOS·
Make Way for the Celtics. 💚
Only In Boston tweet media
English
42
846
8.5K
347.4K
Dr. Aditi Singh retweetledi
Kostas Leventakos
Kostas Leventakos@KLeventakos·
Diets | New England Journal of Medicine nejm.org/doi/full/10.10… Excellent paper on diets. Robust evidence for Mediterranean diet benefits🫒
English
1
2
7
665
Dr. Aditi Singh retweetledi
soria
soria@jsoriamd·
EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #AACR24 @marinagarassino
soria tweet mediasoria tweet media
English
2
31
96
15.3K
Dr. Aditi Singh retweetledi
soria
soria@jsoriamd·
#ASCO24 environmental signatures in non-smoking lung cancer in Asia
soria tweet media
English
0
26
76
14.8K
Dr. Aditi Singh retweetledi
Jennifer A. Marks, MD
Jennifer A. Marks, MD@jennifermarksmd·
Management of pregnancy w/ 🫁ca 🚫 1st trimester ✅Dose according to actual body weight ✅Maintain dose intensity 🚫increase/decrease the dose 🚫chemotherapy @ 35-37 of gestation ✅minimum 3-week interval between the last cycle➡️delivery 🚫avoid IO in 2/3 trim 👀🫁-@matteolambe @asco #ASCO24 #lcsm
Jennifer A. Marks, MD tweet mediaJennifer A. Marks, MD tweet mediaJennifer A. Marks, MD tweet media
English
4
13
32
2.6K